Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2296 to 2310 of 7710 results

  1. Mepolizumab for reducing eosinophilic exacerbations of chronic obstructive pulmonary disease [ID1237]

    Awaiting development [GID-TA10239] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: 20 August 2025

    Technology appraisal guidance
    In development

  3. Leadless cardiac pacemaker implantation for bradyarrhythmias

    Awaiting development [GID-IPG10340] Expected publication date: 13 November 2025

    Interventional procedures guidance
    Awaiting development

  4. Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer

    Awaiting development [GID-IPG10412] Expected publication date: 13 November 2025

    Interventional procedures guidance
    Awaiting development

  5. Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults

    In development [GID-IPG10411] Expected publication date: 06 August 2025

    Interventional procedures guidance
    In development

  6. Balloon cryoablation for Barrett's oesophagus

    Awaiting development [GID-IPG10413] Expected publication date: TBC

    Interventional procedures guidance
    Awaiting development

  7. Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373]

    In development [GID-TA11439] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a cancer drug in people 12 years and over (managed access review of TA742) [ID6288]

    In development [GID-TA11398] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Tolebrutinib for treating relapsing multiple sclerosis ID6351

    Awaiting development [GID-TA11333] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Compression products for treating venous leg ulcers: late stage assessment

    In development [GID-HTE10048] Expected publication date: 27 August 2025

    Health technology evaluations
    In development

  11. Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]

    Awaiting development [GID-TA10700] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Pneumonia: diagnosis and management (update)

    In development [GID-NG10357] Expected publication date: TBC

    NICE guideline
    In development

  13. Linaclotide acetate for treating Chronic idiopathic constipation [TS ID 12005]

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Baloxavir marboxil for Influenza

    Awaiting development [GID-TA11646] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Evinacumab for treating homozygous familial hypercholesterolemia in children aged 5 to 11 TS ID 11806

      Status ...

    Technology appraisal guidance
    Topic selection